Description: Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.
Home Page: www.samjinpharm.co.kr
121 Wausan Ro
Seoul,
04054
South Korea
Phone:
82 2 3140 0700
Officers
| Name | Title |
|---|---|
| Yong-Joo Choi | CEO & Director |
| Gyung-Ho Cheon | Sr. Managing Director |
| Hyun-Nam Myung | Sr. Managing Director |
| Gab-Jin Lee | Managing Director |
| Tae-Sub Shin | Managing Director |
| Jong-Moo Woo | Managing Director |
| Ik-Ju Choi | Sr. Managing Director |
| Hee-Jong Shin | Sr. Managing Director and Head of Laboratory |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4346 |
| Price-to-Sales TTM: | 1.9584 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 586 |